Management of Adult Patients Supported with Venovenous Extracorporeal Membrane Oxygenation (VV ECMO): Guideline from the Extracorporeal Life Support Organization (ELSO)

Tonna, Joseph E.; Abrams, Darryl; Brodie, Daniel; Greenwood, John C.; Mateo-Sidrón, Jose Alfonso Rubio; Usman, Asad; Fan, Eddy

doi:10.1097/mat.0000000000001432

Cited by 370 publications

(366 citation statements)

References 38 publications

Supporting

Mentioning

343

Contrasting

Unclassified

Order By: Relevance

“…In our centre, in line with Extracorporeal Life Support Organization recommendations, prolonged mechanical ventilation is considered a relative contraindication for ECMO (>7 days), but we do not consider a specific time on mechanical ventilation as an absolute contraindication. 4 Data suggest that selected patients can benefit from ECMO even after prolonged periods of mechanical ventilation. 5 …”

mentioning

confidence: 99%

Cytokine adsorption and ECMO in patients with COVID-19 – Author's reply

Supady

2021

The Lancet Respiratory Medicine

View full text Add to dashboard Cite

mentioning

confidence: 99%

Cytokine adsorption and ECMO in patients with COVID-19 – Author's reply

Supady

2021

The Lancet Respiratory Medicine

View full text Add to dashboard Cite

“…The reasons for conversion observed in this study were multifactorial and included inadequate drainage, inadequate perfusion and myocardial infarction followed by hypovolemic-, cardiogenic-and septic shock. As previously discussed, the cardiac involvement in COVID-19 has been highlighted in several studies although it is still partially underestimated in clinical practice as reflected by the recent guidelines [39].…”

Section: Discussionmentioning

confidence: 98%

Transition from Simple V-V to V-A and Hybrid ECMO Configurations in COVID-19 ARDS

et al. 2021

View full text Add to dashboard Cite

In SARS-CoV-2 patients with severe acute respiratory distress syndrome (ARDS), Veno-Venous Extracorporeal Membrane Oxygenation (V-V ECMO) was shown to provide valuable treatment with reasonable survival in large multi-centre investigations. However, in some patients, conversion to modified ECMO support forms may be needed. In this single-centre retrospective registry, all consecutive patients receiving V-V ECMO between 1 March 2020 to 1 May 2021 were included and analysed. The patient cohort was divided into two groups: those who remained on V-V ECMO and those who required conversion to other modalities. Seventy-eight patients were included, with fourteen cases (18%) requiring conversions to veno-arterial (V-A) or hybrid ECMO. The reasons for the ECMO mode configuration change were inadequate drainage (35.7%), inadequate perfusion (14.3%), myocardial infarction (7.1%), hypovolemic shock (14.3%), cardiogenic shock (14.3%) and septic shock (7.1%). In multivariable analysis, the use of dobutamine (p = 0.007) and a shorter ICU duration (p = 0.047) predicted the conversion. The 30-day mortality was higher in converted patients (log-rank p = 0.029). Overall, only 19 patients (24.4%) survived to discharge or lung transplantation. Adverse events were more common after conversion and included renal, cardiovascular and ECMO-circuit complications. Conversion itself was not associated with mortality in the multivariable analysis. In conclusion, as many as 18% of patients undergoing V-V ECMO for COVID-19 ARDS may require conversion to advanced ECMO support.

show abstract

“…ECMO as a BTT was managed as recommended by the Extracorporeal Life Support Organization [15]. The indication for BTT was refractory hypoxemia, hypercarbia, or right heart failure despite optimal medical treatment in candidates for lung transplantation.…”

Section: Ecmo Protocolmentioning

confidence: 99%

“…The 41 patients successfully bridged to lung transplantation had a median bridging time of 13 days (IQR, [7][8][9][10][11][12][13][14][15][16][17][18][19]. Of these 41 patients, 21 (51.2%) required pre-transplant ECMO support for < 14 days (ST-BTT group) and 20 (48.8%) required for � 14 days (LT-BTT group) (Table 2).…”

Section: Comparison Of Variables Between the Short-and The Long-term Btt Groupsmentioning

confidence: 99%

“…The median bridging time in the BTT group was 13 days (interquartile range [IQR], 7-19 days). Although simplified acute physiologic score II was significantly higher in the BTT group (median, 35; IQR,(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)12; IQR,(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) in non-BTT group; p<0.001), 1-year (73.2% vs. 80.6%; p = 0.361) and 5-year (61.5% vs. 61.5%; p = 0.765) post-transplant survival rates were comparable in both groups. Comparison of ST-and LT-BTT subgroups showed that 1-year (90.5% vs. 55.0%; p = 0.009) and 5-year (73.0% vs. 48.1%; p = 0.030) post-transplant survival rates were significantly higher in ST-BTT group.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effects of the duration of bridge to lung transplantation with extracorporeal membrane oxygenation

Hong

Shim

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Background Although bridge to lung transplantation (BTT) with extracorporeal membrane oxygenation (ECMO) is increasingly performed, the impact of BTT and its duration on post-transplant outcomes are unclear. Methods We retrospectively reviewed medical records of adult patients who underwent lung or heart-lung transplantation in our institution between January 2008 and December 2018. Data were compared in patients who did (n = 41; BTT) and did not (n = 36; non-BTT) require pre-transplant ECMO support. Data were also compared in patients who underwent short-term (<14 days; n = 21; ST-BTT) and long-term (≥14 days; n = 20; LT-BTT) BTTs. Results Among 77 patients included, 51 (66.2%) were male and median age was 53 years. The median bridging time in the BTT group was 13 days (interquartile range [IQR], 7–19 days). Although simplified acute physiologic score II was significantly higher in the BTT group (median, 35; IQR, 31–49 in BTT group vs. median, 12; IQR, 7–19 in non-BTT group; p<0.001), 1-year (73.2% vs. 80.6%; p = 0.361) and 5-year (61.5% vs. 61.5%; p = 0.765) post-transplant survival rates were comparable in both groups. Comparison of ST- and LT-BTT subgroups showed that 1-year (90.5% vs. 55.0%; p = 0.009) and 5-year (73.0% vs. 48.1%; p = 0.030) post-transplant survival rates were significantly higher in ST-BTT group. In age and sex adjusted model, the LT-BTT was an independent risk factor for 1-year post-transplant mortality (hazard ratio, 3.019; 95% confidence interval, 1.119–8.146; p = 0.029), whereas the ST-BTT was not. Conclusions Despite the severe illness, the BTT group showed favorable post-transplantation outcomes, particularly those bridged for less than 14 days.

show abstract

Management of Adult Patients Supported with Venovenous Extracorporeal Membrane Oxygenation (VV ECMO): Guideline from the Extracorporeal Life Support Organization (ELSO)

Cited by 370 publications

References 38 publications

Cytokine adsorption and ECMO in patients with COVID-19 – Author's reply

Cytokine adsorption and ECMO in patients with COVID-19 – Author's reply

Transition from Simple V-V to V-A and Hybrid ECMO Configurations in COVID-19 ARDS

Effects of the duration of bridge to lung transplantation with extracorporeal membrane oxygenation

Contact Info

Product

Resources

About